10-QPeriod: Q3 FY2014

AXON ENTERPRISE, INC. Quarterly Report for Q3 Ended Sep 30, 2014

Filed November 5, 2014For Securities:AXON

Summary

TASER International, Inc. (now Axon Enterprise, Inc.) reported strong growth in its third quarter of 2014, with net sales increasing by 26.0% year-over-year to $44.3 million. This revenue growth was primarily driven by significant increases in sales of its TASER X26P Smart Weapon and continued adoption of its EVIDENCE.com and AXON camera solutions. The company also saw a notable expansion in its EVIDENCE.com & Video segment, with revenue up 21.5% and bookings for AXON and EVIDENCE.com products surging significantly. Profitability also improved, with Net Income rising by 47.8% to $7.6 million, or $0.14 per diluted share. This was supported by a stronger gross margin of 64.7% and a decrease in Selling, General, and Administrative (SG&A) expenses as a percentage of sales, despite increased investment in Research and Development (R&D) for the EVIDENCE.com platform. The company's balance sheet remains solid, with $38.6 million in cash and cash equivalents, and it is actively managing its capital through a stock repurchase program.

Financial Statements
Beta

Key Highlights

  • 1Net sales increased by 26.0% to $44.3 million for the three months ended September 30, 2014, compared to $35.2 million in the prior year period.
  • 2Net income grew by 47.8% to $7.6 million ($0.14 per diluted share) for the three months ended September 30, 2014, compared to $5.1 million ($0.10 per diluted share) in the prior year period.
  • 3Gross margin improved to 64.7% from 62.8% in the prior year's third quarter, driven by increased sales and ASPs, and leverage in overhead.
  • 4EVIDENCE.com & Video segment revenue increased 21.5% to $4.3 million, with bookings for AXON and EVIDENCE.com products showing substantial growth to $15.3 million.
  • 5Research and Development (R&D) expenses increased by 54.1% to $3.8 million, reflecting continued investment in the EVIDENCE.com platform.
  • 6The company repurchased $2.9 million of its common stock during the quarter ended September 30, 2014, as part of a $30 million authorization.
  • 7Cash and cash equivalents stood at $38.6 million as of September 30, 2014.

Frequently Asked Questions